Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical TrialAnne Montfort, Thomas Filleron, Mathieu Virazels, et al.
Clinical and Translational Radiation Oncology|April 6, 2019
The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancerVincent Esteyrie, Baptiste Gleyzolle, Amélie Lusque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckChristophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Investigational New Drugs|May 16, 2020
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatmentJean-Pierre Delord, Guillem Argilés, Jerôme Fayette, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.
Cancers|August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis BlockadeCarlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Clinical and Translational Science|March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancerCarlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Pageof 18